Telix to acquire QSAM Biosciences for $123.1m

08 Feb 2024
www.pharmaceutical-technology.com
Orphan DrugAcquisition
Telix to acquire QSAM Biosciences for $123.1m
Preview
Source: Pharmaceutical Technology
QSAM focuses on the development of therapeutic radiopharmaceuticals for primary and metastatic bone cancer. Credit: Komsan Loonprom / Shutterstock.com.
Australia-based global biopharmaceutical company Telix Pharmaceuticals has agreed to acquire US-based QSAM Biosciences for $123.1m.
The deal comes after the companies signed a conditional non-binding term sheet for the prospective acquisition.
Telix will also acquire QSAM’s lead investigational drug, Samarium-153-DOTMP (¹⁵³Sm-DOTMP), a new kit-based bone-seeking targeted radiopharmaceutical candidate.
The acquisition terms include an upfront payment of $33.1m (A$50.8m), payable as 4,369,914 ordinary shares of Telix.
The deal also comprises contingent value rights that could see additional payments of $90m on meeting clinical and commercial milestones. These payments may be made in cash and/or shares.
See Also:Jazz Pharmaceuticals to acquire Redx’s KRAS inhibitorKRAS inhibitor programme
Telix to acquire QSAM Biosciences for $123.1m
Preview
Source: Pharmaceutical Technology
Telix to acquire QSAM Biosciences for $123.1m
Preview
Source: Pharmaceutical Technology
QSAM focuses on the development of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.
Its ¹⁵³Sm-DOTMP for bone cancer has applications in pain management and therapy for bone metastases and osteosarcoma, including for paediatric patients.
It complements Telix’s focus on oncology therapies and has shown promising safety, efficacy and commercial potential in early trials.
The drug also has an improved safety profile, delivery and optimised production.
Recent data suggest ¹⁵³Sm-DOTMP’s efficacy in managing prostate cancer bone metastases pain, addressing a critical unmet need.
Telix also sees potential benefits for patients with metastatic lung and breast cancer, focusing on palliative care and quality of life.
The US Food and Drug Administration (FDA) granted orphan drug and rare paediatric disease designations for ¹⁵³Sm-DOTMP to treat osteosarcoma.
Telix managing director and group CEO Dr Christian Behrenbruch stated: “The acquisition of QSAM provides Telix with an additional near-term therapeutic pipeline asset, further differentiating our innovation position in radiopharmaceuticals and building depth in Telix’s key disease focus areas of urological and musculoskeletal oncology.
“Samarium is a highly optimal radionuclide for treating bone metastases, and the combination of orphan drug designation and rare paediatric disease designation status with Telix’s demonstrated experience in pharmacy-based cold-kit distribution has strong potential for a rapid pathway to commercialisation of this asset.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.